Hydroxyurea blunts mitochondrial energy metabolism and osteoblast and osteoclast differentiation exacerbating trabecular bone loss in sickle cell mice
Ashish Kumar Tripathi, Sadaf Dabeer, Jun Song, Tatyana Vikulina, Susanne Roser-Page, Jessica A Alvarez, David R Archer, M Neale Weitzmann · 2024
Read Hydroxyurea blunts mitochondrial energy metabolism and osteoblast and osteoclast differentiation exacerbating trabecular bone loss in sickle cell mice by Ashish Kumar Tripathi, Sadaf Dabeer, Jun Song, Tatyana Vikulina, Susanne Roser-Page, Jessica A Alvarez, David R Archer, M Neale Weitzmann (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11655664.txt.
Description
Ashish Kumar Tripathi and co-authors test a front line sickle cell drug for bone effects in mice in this 2024 paper. Sickle cell disease causes red cells to bend and block blood flow. Bone loss is common, especially in the spine, and leads to fractures. Whether hydroxyurea helps or harms bone was not established.
The team used Townes mice, a standard model of the disease. High resolution scans measured cortical and trabecular bone in vertebrae. Sick mice lost cortical bone at all ages, and adults also lost trabecular bone. The drug eased cortical loss in adults. It worsened trabecular loss in both age groups, though. Cell tests showed the drug blunted energy use in bone building and bone clearing cells.
Catalog record
| CREATOR | Ashish Kumar Tripathi, Sadaf Dabeer, Jun Song, Tatyana Vikulina, Susanne Roser-Page, Jessica A Alvarez, David R Archer, M Neale Weitzmann |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |